ライフサイエンスコーパス: joint pain

1 depression, smoking, alcohol use, and other joint pain).

2 s can be altered significantly by changes in joint pain.

3 in elasticity, tissue fragility, and chronic joint pain.

4 p emphasizing nonpharmacologic management of joint pain.

5 erized by an acute febrile phase and chronic joint pain.

6 gue without exacerbating disease activity or joint pain.

7 tes robust oral activity in rodent models of joint pain.

8 made between subjects with and those without joint pain.

9 al and central sensitization contributing to joint pain.

10 ritis are accompanied by significant chronic joint pain.

11 cules that mediate osteoarthritis-associated joint pain.

12 ature about obesity, knee osteoarthritis and joint pain.

13 f articular cartilage accompanied by chronic joint pain.

14 0.74-0.81) for the 267 participants with no joint pain.

15 P-13 inhibitors on cartilage degradation and joint pain.

16 subjectively better control of the rash and joint pain.

17 t pathology and attenuation of the attendant joint pain.

18 with objective measures of skin clearance or joint pain.

19 enes for the management of temporomandibular joint pain.

20 emoved from the study because of intolerable joint pain.

21 the 300 participants with 2 or more sites of joint pain, 0.90 (95% CI, 0.87-0.92) for the 181 partici

22 tibody (2 points), and absence of peripheral joint pain (1 point).

23 39% (23-57), and 86% (56-93), respectively; joint pain 14% (11-18), 42% (26-60), and not available,

24 %), dermatitis (25.3%), oral ulcers (24.2%), joint pain (23.0%), pleural effusion (16.5%) and increas

25 e seronegative population; P<.001), bone and joint pain (27% vs. 9%; P<.001), headache (27% vs. 12.3%

26 41 (5%) had fatigue, 41 (5%) had muscle and joint pains, 37 (5%) had nausea, 36 (4%) had vomiting, 3

27 [corrected] [13%] vs 85 [corrected] [12%]), joint pain (41 [corrected] [6%] vs 38 [5%]), infection (

28 gue (74%; grades 2 and 3 in 19% and 2%), and joint pain (63%; grades 2 and 3 in 19% and 0%).

29 llows: pruritus (95 %), skin burning (81 %), joint pain (69%), arthritis (51%), and psoriatic arthrit

30 loss of appetite (87.0%), headache (77.9%), joint pain (73.7%), vomiting (71.2%), and diarrhea (70.6

31 ycycline did not reduce the mean severity of joint pain, although pain scores in both treatment group

32 survey, 94 (47%) reported having AI-related joint pain and 88 (44%) reported AI-related joint stiffn

33 during inflammatory arthritis and results in joint pain and bone malformations.

34 tanezumab was associated with a reduction in joint pain and improvement in function, with mild and mo

35 Joint pain and poor functional status were the most comm

36 Relieving joint pain and preventing its recurrence are primary aim

37 or acute neuroborreliosis more often now had joint pain and sleep difficulty and lower scores on the

38 ikely than other patients to have AI-related joint pain and stiffness (odds ratio [OR] = 4.08, 95% CI

39 eated with TA had significant improvement of joint pain and stiffness, which was not seen with SA.

40 rmone-sensitive breast cancer, but can cause joint pain and stiffness.

41 on adverse events were a short-term flare in joint pain and swelling following treatment, a side effe

42 Characterized by acute fever with joint pain and swelling, most patients recover from this

43 oman, was seen with urticaria and associated joint pain and swelling.

44 nal study to describe the characteristics of joint pain and to examine the relationship between QST m

45 ivity measures (daily diary reports of rash, joint pain and/or swelling, and fevers), health quality

46 tective effects and can potentially modulate joint pain, and are, therefore, uniquely suited as poten

47 presentations such as severe back and small joint pain, and debilitating arthritis associated with c

48 ue, nausea, liver pain, anorexia, muscle and joint pain, and general health remained significantly be

49 sociated with severity of pruritus, burning, joint pain, and psoriatic arthritis.

50 ge, increasing fat mass (in kilograms), knee joint pain, and reduced quadriceps strength.

51 age, fibromyalgia, apophyseal and sacroiliac joint pain, and sacral insufficiency fractures.

52 hich is associated with cold-induced fevers, joint pain, and systemic inflammation.

53 Overall, fever, joint pain, and/or night sweats were reported in 27 (47%

54 severe form of HFMD associated with fevers, joint pains, and widespread painful eruptions.

55 lationship between occupational hand use and joint pain; and the extent of occupational hand use amon

56 Patient-reported flare, joint pain at rest, warm joints, and swollen joints were

57 tion, it is essential that the management of joint pain be considered in light of the impact of multi

58 s the duration and severity of abdominal and joint pain, but corticosteroids do not prevent the devel

59 s of education on walking knee pain, overall joint pain (by HAQ), and general health status (by QWB)

60 AIMSS with duloxetine would improve average joint pain compared with placebo.

61 Dry skin, fatigue, itching, and bone/joint pain each were reported by > or =50% of patients.

62 ), osteoarthritis (7.1 million), nonspecific joint pain/effusion (7.0 million), and rheumatoid arthri

63 injection, one patient experienced moderate joint pain exacerbation that resolved spontaneously.

64 and a syndrome comprising diffuse muscle and joint pain, fever, lethargy and anorexia.

65 revalent joint disease and a common cause of joint pain, functional loss, and disability.

66 valent joint disease and a frequent cause of joint pain, functional loss, and disability.

67 ng in appropriate sites and other causes for joint pain have been excluded.

68 orted higher rates of physical symptoms (eg, joint pains, headaches, and hot flashes) than healthy wo

69 All investigated symptoms except joint pain improved after diagnosis and initiated gluten

70 administration of GW3965 potently alleviated joint pain in a rat meniscal tear model of osteoarthriti

71 ) had more joint pain (odds ratio for having joint pain in any joint, 2.1 [CI, 1.2 to 3.5]; P = 0.007

72 that causes acute febrile illness and severe joint pain in humans.

73 Joint pain in older adults is a problem commonly present

74 s of brief, simple assessment and staging of joint pain in older adults.

75 described and discussed their experience of joint pain in the context of standard self-assessment qu

76 r three months before admission, followed by joint pains in her knees, elbows and several proximal in

77 hree of eight patients treated at 175 mg/m2 (joint pains in two, skin in one).

78 Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Un

79 Further study of therapy-induced joint pain is necessary.

80 Similar patterns were observed for worst joint pain, joint stiffness, pain interference, and func

81 ded injection-site AEs from days 1 to 5, and joint pain, joint swelling, vesicular lesions (blisters)

82 interest of Latinos in various arthritis and joint pain management programs could prove to be an impo

83 ficacious in the acute model and the chronic joint pain model.

84 erized by gastrointestinal symptoms, chills, joint pain, myalgia, thrombocytopenia, leukocytopenia, a

85 with American Indians who experience chronic joint pain (n = 56), to elicit descriptions and self-rep

86 ion to study evaluation, 6.0 years) had more joint pain (odds ratio for having joint pain in any join

87 on of the foot or ankle, and 14.9% had ankle joint pain on most days in the past 4 weeks.

88 mined by a rheumatologist because of chronic joint pain or evidence of small-vessel disease (0.7%).

89 nt or physician assessment), joint swelling, joint pain or tenderness, erythrocyte sedimentation rate

90 (OR 1.27; 95% CI 0.08, 19.63) or prevent new joint pains (OR 0.72; 95% CI 0.11, 4.68) in RA participa

91 n EM was present, during initial episodes of joint pain, or during the maximal period of arthritis.

92 ere in the body influences the experience of joint pain, pain is inextricable from function, and adap

93 However, in some patients, joint pain persists, lasting for months or even years.

94 ting illness in 7-10 days, with cessation of joint pain post-acute episode.

95 at emphasized nonpharmacologic management of joint pain, preservation of function by problem-solving,

96 characterised by fever, headache, muscle and joint pains, rash, nausea, and vomiting.

97 novium, as well as a significant increase in joint pain-related behaviors.

98 isted after adjustment for CVD risk factors, joint pain, rheumatoid factor positivity, and inflammato

99 arly-stage breast cancer and who had average joint pain score of >/= 4 out of 10 that developed or wo

100 By 12 weeks, the average joint pain score was 0.82 points lower for patients who

101 the Short Form 36 (SF-36) and self-reported joint pain scores at baseline and after 1 year.

102 Worst joint pain scores decreased by 1.6 points (29%) at 12 mo

103 Nonsignificant improvements in joint pain scores were seen with PHT use (odds ratio [OR

104 Joint pain (sensitivity, 85%; 95% confidence interval [C

105 n routine clinical settings and across other joint pain sites, our findings suggest that focal charac

106 reast cancer receiving an AI who had a worst joint pain/stiffness score >/= 5 of 10 using the Brief P

107 Data on overall joint pain, swelling and stiffness, and activities of da

108 n, elbow, knee and metacarpophalangeal (MCP) joint pain, swelling, and/or deformity, and radiographic

109 codes 715, 716, or 719, and if they reported joint pain, swelling, or stiffness during the previous 1

110 typically induced by cold (rash, fever, and joint pain/swelling) improved within days of rilonacept

111 rns and calluses, fungal signs, edema, ankle joint pain, tenderness to palpation, and sensory loss.

112 Treatment response was based on joint pain/ tenderness and swelling scores and physician

113 efinition of treatment response was based on joint pain/tenderness and swelling scores and physician

114 n in patients with axial manifestations, and joint pain/tenderness scores and joint swelling scores i

115 ional hand use were more likely to have hand joint pain than those with moderate hand use (66% versus

116 g disease in humans characterized by intense joint pain that can persist for weeks, months, or even y

117 fected with CHIKV suffer from incapacitating joint pain that severely affects their daily functioning

118 The primary end point was average joint pain through 12 weeks, examined using multivariabl

119 ed to calculate 3-dimensional moments at the joints; pain, using a separate visual analog scale for e

120 An increase in bone or joint pain was more pronounced, particularly in the shor

121 Joint pain was not generally assumed to be arthritis nor

122 Severity of joint pain was recorded at 6-month intervals.

123 Joint pain was reported by 10% of subjects recently HIV

124 s in fatigue were correlated with decreasing joint pain, whereas improvements in symptoms of depressi

125 phavirus, causes febrile disease, muscle and joint pain, which can become chronic in some individuals

126 Therapeutic modulation of chronic facet joint pain with the use of various pharmacologic agents

127 tal of 66.2% of the subjects reported recent joint pain, with a median average pain severity of 5 of